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Levels
Abstract
Introduction: To examine the relationship between elevated basal serum tryptase levels (BST), a marker
of total mast cell mass, and bone mineral density (BMD) in patients with anaphylactic reactions and
signs of mastocytosis. Methods: Retrospective evaluation of patient charts at an allergy unit. Patients
with BST levels above 20 ng/ml were eligible if clinical and follow-up data and results of dual X-ray
absorptiometry (DXA) were available. Patients with previous use of anti-osteoporotic medications and
with osteoporosis not caused by mastocytosis were excluded. Spearman's rank correlation,
Mann-Whitney test and receiver operating characteristic curve (ROC) was used for analysis. Results: 24
patients were included. The main presenting symptom (17 of 24 patients) was anaphylactic reactions to
insect stings. BST levels ranged between 21 and 158 ng/ml (median 48 ng/ml). Study participants with
Z-score values below - 1.0 had a median BST level of 46 ng/ml, the patients with Z-score values above
or equal to -1.0 had a median BST level of 27 ng/ml. ROC analysis of the patient group with BST values
between 30 and 100 ng/ml revealed a best cut-off value of BST to detect a low BMD when BST level
would be at least 27 ng/ml resulting in a sensitivity of 92% and a specificity of 70%. Conclusion:
Patients with moderately elevated BST levels seem to be at increased risk for low BMD.
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Abstract: 
Introduction: To examine the relationship between elevated basal serum tryptase levels (BST), a marker of total mast cell 
mass, and bone mineral density (BMD) in patients with anaphylactic reactions and signs of mastocytosis. 
Methods: Retrospective evaluation of patient charts at an allergy unit. Patients with BST levels above 20 ng/ml were eli-
gible if clinical and follow-up data and results of dual X-ray absorptiometry (DXA) were available. Patients with previous 
use of anti-osteoporotic medications and with osteoporosis not caused by mastocytosis were excluded. Spearman’s rank 
correlation, Mann-Whitney test and receiver operating characteristic curve (ROC) was used for analysis. 
Results: 24 patients were included. The main presenting symptom (17 of 24 patients) was anaphylactic reactions to insect 
stings. BST levels ranged between 21 and 158 ng/ml (median 48 ng/ml). Study participants with Z-score values below -
1.0 had a median BST level of 46 ng/ml, the patients with Z-score values above or equal to -1.0 had a median BST level 
of 27 ng/ml. ROC analysis of the patient group with BST values between 30 and 100 ng/ml revealed a best cut-off value 
of BST to detect a low BMD when BST level would be at least 27 ng/ml resulting in a sensitivity of 92% and a specificity 
of 70%. 
Conclusion: Patients with moderately elevated BST levels seem to be at increased risk for low BMD.  
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INTRODUCTION 
Mastocytosis, a heterogeneous disease, can cause accu-
mulation of mast cells in one or more organs. It is one of the 
causes of secondary osteoporosis. Skeletal changes in pa-
tients with mastocytosis may be generalised or localized. 
Osteoporosis, osteosclerosis, or a combination of osteolytic 
and osteosclerotic lesions may be found [1-4]. In the late 
1990’s, measurement of total serum tryptase values became 
available. Levels of serum tryptase measured outside of epi-
sodes of anaphylaxis (hence corresponding to ‘basal’ blood 
values) are thought to represent the total mast cell burden of 
an individual and are usually elevated in patients with sys-
temic forms of mastocytosis [5]. A basal serum tryptase 
(BST) value above twenty nanograms per millilitre is con-
sidered a minor criterion for the diagnosis of systemic mas-
tocytosis [6].  
 
 
*Address correspondence to this author at the Institute of Medical Radiol-
ogy, Buergerspital Solothurn/ Spital Grenchen soH, Schoengruenstrasse 42, 
4500 Solothurn, Switzerland; Tel: +41 032 627 41 00; Fax: +41 032 627 41 
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There are various possible pathophysiologic links be-
tween mastocytosis and low bone mass. For example in-
volvement of the gastrointestinal tract may cause malabsorp-
tion leading to bone loss. Involvement of the bone marrow is 
found very often in patients with urticaria pigmentosa but 
can also be observed in patients without skin manifestations 
[7]. There are many different metabolites produced by mast 
cells such as heparin or prostaglandins which may facilitate 
bone resorption. Other metabolites such as cytokines influ-
ence the maturing of osteoblast and osteclasts, thus impact-
ing also on bone mass itself [2]. In contrast, it is uncommon 
to find osteoporosis as the main clinical manifestation of 
mastocytosis [1]. Recently, recommendations for the use of 
bone densitometry have been published [8-10]. According to 
the official positions of the International Society for Clinical 
Densitometry (ISCD) measurement of bone mineral density 
(BMD) using Dual X-ray Absorptiometry (DXA) should be 
considered in women 65 years of age and older, in post-
menopausal women under the age of 65 with risk factors, 
and in men 70 years of age an older. Additionally, patients 
with diseases or conditions associated with a low bone mass 
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or bone loss and patients taking medication associated with 
these findings should be considered to undergo BMD testing 
[8-10]. Patients presenting in the allergy unit of the univer-
sity hospital Zurich with mastocytosis and/or elevated BST 
levels were often, but at the time of this study not routinely 
referred for BMD testing. DXA was especially performed if 
there were additional clinical signs or risk factors for osteo-
porosis (in particular older age, postmenopausal status, bone 
pain/ back pain, positive family history for osteoporosis, and 
use of corticosteroids).  
The objective of this retrospective study was to examine 
the relationship between BST levels and BMD as measured 
by DXA and to assess the long-term outcome in these pa-
tients with anaphylaxis and other signs of mastocytosis, re-
spectively. Furthermore, follow-up regarding the use of anti-
osteoporotic medications and occurrence of non-traumatic 
fractures was assessed. 
METHODS 
Selection of Patients 
Patients undergoing blood measurement of BST levels 
between January 1998 and June 2003 were selected from the 
files of the Allergy Laboratory of the Department of Derma-
tology. Patients were included in this retrospective study if 
they had had at least once a BST level above 20 ng/ml, and if 
DXA measurements and clinical follow-up data were avail-
able (from patient charts and by telephone calls). Only pa-
tients were included, for which could be ascertained that 
tryptase levels were true basal levels, and not determined 
during an anaphylactic reaction. All of the eligible patients 
agreed to be included into the study and gave their informed 
written consent (‘study participants’). Exclusion criteria were 
prior use of bisphosphonates or other anti-osteoporotic 
agents within the previous five years and obvious secondary 
causes of osteoporosis such as long-term use of high doses of 
corticosteroids, use of antiepileptic drugs, malabsorption, 
malnutrition, chronic alcohol abuse, endocrine disorders 
(like hypogonadism, hyperthyroidism, Cushing’s Syn-
drome), and malignant bone disease (e.g. multiple mye-
loma). Patients were also excluded when treated with inter-
feron alpha 2b and if the BST values normalised during fol-
low up. The following data were collected from the patient 
chart: age, body mass index, presenting symptoms, symp-
toms of mastocytosis, laboratory values use of alcohol and 
cigarettes, medications, past history, family history, and 
other risk factors for osteoporosis. 
BST Measurements 
BST was measured on the CAP system according to the 
recommendations of the manufacturer (Phadia Diagnostics, 
Uppsala, Sweden). This assay measures both the alpha- and 
the beta-tryptase (‘total tryptase’). The alpha-protryptase is 
constitutively secreted and is the type of tryptase found in 
the serum of normal, healthy individuals [5]. Therefore, the 
level of the alpha-protryptase constitutes the ‘basal serum 
tryptase level’ and is thought to reflect the total mast cell 
burden [11]. Mature beta-tryptase can be measured in serum 
during systemic allergic reactions and indicates degranula-
tion of mast cells. In all of our patients tryptase was deter-
mined at least three days after an anaphylactic reaction and, 
therefore, corresponds to BST levels [12, 13]. Normal BST 
values are below 11.4 ng/ml according to the manufacturer.  
Measurement of BMD  
DXA is considered being the reference standard for de-
termination of bone mineral density (BMD) and was used in 
all of our patients [8-10, 14]. The lumbar spine measurement 
was taken from dorsal projection. The regions of interest 
(ROI) at the lumbar spine were in the vertebral bodies L2 – 
L4. In the hip ROI were total hip, neck, trochanteric region, 
and Ward`s triangle. If measurement was not possible at the 
lumbar spine or hip, an additional measurement of the non-
dominant forearm was acquired according to the Official 
Positions of the ISCD [8-10]. Measurements were done with 
a Hologic QDR 4500 A and C™ device (Hologic Inc., 
Waltham, MA). For quality control of the DXA devices, a 
spine phantom was used on a daily base according to the 
recommendations of the manufacturer. 0.5% variability from 
the mean value was considered a tolerable variation of the 
DXA measurements for the longitudinal control. DXA 
measurements in four of the 24 participants were undertaken 
at two large district hospitals in the German-speaking region 
of Switzerland, using Lunar equipment (GE Medical Sys-
tems, Madison, Wisconsin, USA). BMD was given as abso-
lute values in g/cm
2
, and as Z- and, T-score values. The Z-
score value corresponds to the number of standard deviations 
from the mean value that was defined by the range of BMD 
of an ethnically comparable, age- and gender-matched refer-
ence population. A Z-score value of -2.0 or lower indicates a 
low BMD for chronologic age. The T-score value corre-
sponds to the number of standard deviations from the mean 
BMD of a gender-matched reference population of young 
adults defined as the Peak Bone Mass. In agreement with 
ISCD guidelines, osteopenia or osteoporosis were defined as 
the lowest measured value in either spine or hip. Osteopenia, 
as defined by the WHO classification, corresponds to a T-
score value between -1.0 and -2.5. Osteoporosis was defined 
as a T-score value of -2.5 or lower. Low bone mass is de-
fined as all T-score values indicating osteopenia or osteopo-
rosis. 
Follow Up Assessment 
In April and May 2007, all participants were contacted 
by telephone and interviewed about use of anti-osteoporotic 
medications, occurrence of fractures and the course of the 
symptoms of mastocytosis. Follow-up determinations of 
BST and DXA were collected.  
Statistical Analysis 
Analysis of data was done with the SPSS statistical pack-
age, version 12.0 (SPSS Inc., Chicago, Illinois, USA). De-
scriptive statistics (rate, mean/standard deviation, median, 
range) were used to characterize the groups. Because of the 
relatively low mean and median age of study participants Z-
score values served for statistical comparison as suggested in 
the Position Statement of the International Society for Clini-
cal Densitometry [9]. Linear regression was applied to fur-
ther investigate the relationship between BST and Z-score 
values. Spearman’s rank correlation was done for correlation 
analysis between two continuous variables. Mann-Withney 
test served for the comparison between male and female pa-
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tients. Receiver operating characteristic curve (ROC) was 
performed to evaluate the discriminative power of BST lev-
els for the identification of a low BMD (Z-score = -1.0 or 
lower) at lumbar spine and hip.  
RESULTS 
Patient Selection 
133 patients with a BST above 20 ng/ml could be identi-
fied in the time period between January 1998 and June 2003. 
32 of these 133 patients were excluded because blood sam-
ples had been sent from external laboratories and clinics out-
side the Department of Dermatology and, consequently, no 
clinical data was available. Six patients (of whom one with 
DXA measurement) were excluded because their BST re-
turned to normal during follow up. Another two patients 
were excluded because it was not clear whether their ele-
vated tryptase levels were true basal values. One patient was 
excluded because of use of anti-osteoporotic medication. 
Data on BMD as determined by DXA could be retrieved 
for 24 eligible patients (‘study participants’). Characteristics 
of these 24 patients are shown in Table 1. The group of pa-
tients undergoing DXA was similar with respect to age and 
presenting symptoms to the patients not undergoing DXA. In 
both groups more than seventy percent of patients had been 
referred for anaphylactic reactions to insect stings. The 17 
patients presenting with insect sting allergy had already pre-
vious allergic reaction to insect stings, but underwent evalua-
tion for mastocytosis for the first time. The median BST 
level of study participants was 53% higher than the median 
BST of patients without DXA (38.0 vs. 24.9 ng/ml). This 
reflects the appreciation of an elevated BST value to possi-
bly be a risk factor for low bone mass.  
Description of Study Participants 
Characteristics of the 24 study participants are shown in 
Table 2. All patients were of white Caucasian ethnicity. 83% 
of study participants had been referred for anaphylaxis, oc-
curring mainly following bee and yellow jacket stings (Table 
1, presenting symptoms). There was no difference for the 
measured BST levels between male and female patients (p= 
0.34). There was a considerable variation among participants 
with respect to age (range 24 – 83 years), body mass index 
(range 19.1 – 43.2 kg/m2), clinical symptoms of mastocyto-
sis, BST-values (range 21.2 – 158 ng/ml) and results of 
DXA. 
All but two patients (patient 43 and 74) had persistently 
elevated tryptase levels and/or positive bone marrow and/or 
skin biopsy. Patient 43 was documented with two BST val-
ues of 21.5 and 25.8 ng/ml determined with a 7 week inter-
val. Patient 118 was found to have slowly increasing BST 
values (July 1999 13.0 ng/ml, June 2000 16.7 ng/ml, August 
2002 21.7 ng/ml, and February 2003 23.0 ng/ml). In some 
participants with persistently elevated BST values, biopsy 
results were non-conclusive (patients 1 and 47) or even nega-
tive (103, 13, 14, 88). None of the patients had signs of hae-
matological malignancy.  
Measurement of BMD  
14 of 24 study participants (58%) had T-score values be-
low -1.0 (osteopenia), and 6 patients (25%) values below -
2.5 (osteoporosis) (Table 2). Z-scores were on average lower 
for the lumbar spine as compared to the hip measurements 
(p=0.001). There was important variability of Z-score values 
in the lumbar spine region among study participants ranging 
from -3.3 to 2.3. Four patients with age between 24 and 48 
years had a Z-score value of -2.0 or below indicating a low 
BMD for chronologic age. There was no difference for the 
measured Z-score values between male and female patients 
(lumbar spine: p=0.47; total hip: p= 0.49).  
Characteristics of study participants with Z-score values 
below -1.0 are shown in Table 3. Subjects with Z-score val-
ues below -1.0 had a median age of 43 years, the patients 
with Z-score values above or equal to -1.0 49 years. Study 
participants with Z-score values below -1.0 had a median 
BST level of 46 ng/ml, the patients with Z-score values 
above or equal to -1.0 had a median BST level of 27 ng/ml. 
The study participants with Z-score values below -1.0 were 
more likely to have urticaria pigmentosa (42% versus 25%) 
and for a positive bone marrow biopsy. Seven out of nine 
participants with a positive bone marrow biopsy had Z-score 
values below -1.0. Two participants with negative or non 
conclusive results of bone marrow biopsies (patients 103 and 
Table 1. Characteristics of Study Participants (Patients with 
DXA)  
 Patients with DXA 
(n=24) 
Males / females 9 / 15 
       Proportion of females (%) 63 
Age (years)  
       median 48.2 
       mean ± SD 49.4 ± 14 
Basal serum tryptase (ng/ml)  
       median 38.0 
       mean ± SD 49.5 ± 35.5 
Total IgE (Units/liter) (n=17) 
       median 16.6 
       mean ± SD 33.0 ± 52.5  
Presenting symptoms (n  (%))  
       Insect sting allergy 17  (71) 
       Systemic mastocytosis 1 (4) 
       Urticaria pigmentosa 2 (8) 
       Chronic urticaria 1 (4) 
       Quincke’s edema  1 (4)) 
       Osteoporosis 1 (4) 
       Idiopathic anaphylaxis 1(4) 
There were no patients with food allergy or airway disease; SD= Standard Deviation 
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1) had normal lumbar spine Z-score values of -0.3 and 1.7, 
respectively. 
Relationship Between BST and BMD 
Figs. (1a and 1b) show BST values by Z-score values 
measured at the lumbar spine and total hip. There was no 
strong association between BST values and BMD in linear 
regression analysis (r
2
=0.06 for the lumbar spine and 0.16 
for the hip). The slope of the regression lines was negative. 
However, Spearman’s rank correlation revealed a significant 
correlation between lumbar spine BMD and BST level (p= 
0.03) and between total hip BMD and BST level (p= 0.02). 
Table 4 and Fig. (2) show BMD values analysed by BST 
categories. There was no obvious difference between the 
four BST categories with regard to age and BMI. Lowest Z-
score mean values were found for BST values between 30 
and 100 ng/ml. Additionally, receiver operating characteris-
tic curve (ROC) was done for the patient group with BST 
values between 30 and 100 ng/ml (i.e. patients 2, 11, and 90 
with values above 100ng/ml were excluded). ROC revealed 
an area under the curve of 0.78 ± 0.11 for the identification 
of a low BMD at the hip (p=0.03; CI: 0.56 – 0.99) when us-
Table 2. Clinical Characteristics of Study Participants 
Pat-
Nr. 
Sex Age 
Body 
Mass 
Index 
Presenting With  
(in brackets:Mueller 
Grade [12]) 
Signs and 
Symptoms of 
Mastocytosis 
Basal 
Serum 
Tryptase 
T-
score 
Spine 
Z- 
score 
Spine 
T-
score 
Hip 
Z- 
score 
Hip 
Skin 
Biopsy 
Bone 
Marrow 
Biopsy 
             
             
1 f 43 28.7 Quincke Edema P, F, G, N 24.3 1.4 1.7 0.4 0.6 nd +/- 
2 f 64 31.0 Urticaria pigmentosa UP, P 114.0 -0.2 1.6 -0.2 1.0 + nd 
4 f 33 22.2 Insect sting allergy (III) A, Dz, M 60.8 -0.8 -0.7 -0.3 -0.3 nd + 
5 f 42 43.2 Systemic mastocytosis 
A, UP, P, G, 
M, 
38.5 -2.2 -1.8 0.8 1.1 + + 
7 f 35 23.8 Insect sting allergy (IV) 
A, UP, P, M, 
G, D 
46.4 -3.4 -3.3 -2.2 -2.0 + + 
11 f 43 23.1 Insect sting allergy (IV) A, P, F, M 158.0 -1.9 -1.9 -1.5 -1.5 + + 
13 m 54 29.0 Insect sting allergy (IV) A, F, M, G 40.3 0.6 1.1 0.1 0.5 - nd 
14 m 44 25.4 Insect sting allergy (IV) A, F, G, D 45.8 -2.6 -2.4 0.6 1.0 - nd 
16 f 48 26.2 Insect sting allergy (IV) A 37.4 -1.6 -1.0 0.1 0.4 nd nd 
17 f 24 20.5 Osteoporosis P, F, D 28.0 -3.0 -2.9 -1.1 -1.1 + + 
42 f 72 19.1 Insect sting allergy (IV) A, M 21.2 -4.5 -1.8 -2.6 -0.6 nd nd 
43 m 46 26.9 Insect sting allergy (IV) A 21.5 1.9 1.7 1.4 1.5 nd nd 
47 f 37 24.7 Chronic Urticaria M, U, D 26.6 0.4 0.5 1.9 2.0 +/- nd 
49 m 70 27.0 Insect sting allergy (IV) A, M, S 56.0 -1.8 -0.9 -0.2 0.5 nd nd 
54 m 40 31.4 Insect sting allergy (IV) 
A, UP, P, F, 
M, G 
26.5 -0.5 -0.5 0.0 0.1 + nd 
55 f 42 23.1 Insect sting allergy (IV) A, P 25.8 0.5 0.8 -0.1 0.1 nd nd 
74 f 83 32.4 Insect sting allergy (IV) A, M, G 25.4 -0.4 2.3 -0.2 2.0 nd nd 
88 m 62 23.2 Insect sting allergy (IV) A 77.9 -2.6 -1.9 -0.5 -0.1 - + 
90 m 41 25.6 Insect sting allergy (IV) A, UP 116.0 -1.4 -1.6 -0.6 -0.5 + + 
103 f 52 20.5 Insect sting allergy (III) A, F, M 30.9 -1.1 -0.3 0.0 0.6 nd - 
115 f 58 24.5 Urticaria pigmentosa A, UP, F 26.8 0.3 1.5 0.7 1.5 + + 
118 m 35 23.8 Insect sting allergy (IV) A, F, P 21.7 -1.4 -1.4 -0.1 0.0 nd nd 
127 f 48 23.7 Insect sting allergy (IV) A 76.9 -2.6 -2.0 -1.4 -1.0 nd + 
133 m 29 24.8 Idiop. Anaphylaxis A, UP, P, F, D 50.4 -1.4 -1.4 0.2 0.3 + nd 
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ing a BST cut-off value of 20ng/ml and an area under the 
curve of 0.74 ± 0.13 for the identification of a low BMD at 
the lumbar spine (p= 0.02; CI: 0.49 – 0.98) (Fig. 3a and b). 
Using a cut-off point of 30 ng/ml for the BST level, the 
sensitivity to detect a low BMD at the lumbar spine or hip 
was 83% and the specificity 70%. Based on our limited pa-
tient population the best cut-off value of BST to detect a low 
BMD would be a BST level of at least 27 ng/ml resulting in 
a sensitivity of 92% and a specificity of 70%.  
Follow-up Assessment of Participants 
There was a median duration of clinical follow up of 6.6 
years (range 4 to 9 years) after determination of the first BST 
value above 20 ng/ml. Median duration of BST follow up 
was 2.3 years (mean 3.0 years, range 1 to 8 years), and me-
dian number of BST determinations per patient was 3 times 
(range 1 to 7). In most of the patients, BST follow-up values 
remained in a similar range to the initial value, as one would 
expect for patients with indolent systemic mastocytosis.  
Seven patients were prescribed bisphosphonates (patient-
numbers 7, 14, 17, 42, 88, 90, 127) for duration of between 2 
and 7 years. Patient 17 was changed to calcitonin nasal spray 
after two years of bisphosphonate therapy. Eight patients 
reported having been prescribed calcium and vitamin D sup-
plements. The only patient who reported radiologically 
documented fractures was patient 17, a physically active 
young woman. She had acquired several fractures of finger 
bones when snowboarding during wintertime, and reported a 
traumatic ‘fissure’ of the proximal tibia of one side. A non-
traumatic fracture did not occur in any of the patients. She 
was the only patient in our study who presented with osteo-
porosis. Additionally, this patient suffered from chronic diar-
rhoea for duration of four years. She was first misdiagnosed 
as having Crohn’s disease, but later her symptoms were at-
tributed to gastrointestinal involvement of mastocytosis. It is 
well known that gastrointestinal involvement with mastocy-
tosis can lead to malabsorption which may cause bone loss.  
Table 3. Comparison of Study Participants with Z-Score Values < -1.0 in the Region of the Lumbar Spine with Study Participants 
with Z-Score Values  -1.0 
 All patients 
Lumbar Spine 
 Z-Score Value  -1.0  
Lumbar Spine 
 Z-Score Value < -1.0 
Male / female 9 / 15 4 / 8 5 / 7 
   Proportion of females (%) 63 50 58 
Age (years)    
   mean ± SD 49 ± 14 52 ± 15 44 ± 13 
   median (range) 48 (24 - 83) 49 (33 - 83) 43 (24 - 72) 
Body-Mass-Index (kg/m2)    
   mean ± SD 26 ± 5 27 ± 4 25 ± 6 
Urticaria pigmentosa (%) 33 25 42 
Anaphylaxis (%) 83 75 92 
Basal Serum Tryptase (ng/ml)    
   mean ± SD 50 ± 36 40 ± 27 60 ± 42 
   median (range) 38 (21 - 158) 27 (22 - 114) 46 (21 - 158) 
Bone marrow biopsy  (n (%))    
   positive 9 (38) 2 (17) 7 (58) 
   negative / non conclusive 2 (8) 2 (17) 0 (0) 
   not done 13 (54) 8 (66) 5 (42) 
Z-score value  Lumbar Spine    
   mean ± SD -0.6 ± 1.6 0.7 ± 1.1 -2.0 ± 0.6 
Z-score  value  Total Hip    
   mean ± SD 0.3 ± 1.0 0.8 ± 0.8 -0.3 ± 1.0 
Z-score value   Total Hip Neck    
   mean   ± SD 0.0 ± 1.1 0.7 ± 0.9 -0.6 ± 1.0 
n = number of patients; age = age at time of first BST measurement; SD = standard deviation 
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DISCUSSION 
The results of this study show, that the prevalence of os-
teopenia (58%) and osteoporosis (25%) is high in patients 
with elevated BST levels presenting with severe anaphylac-
tic reactions and other signs of mastocytosis. The group of 
Dean Metcalfe from the NIH examined the relationship be-
tween BST levels and Z-score values in different categories 
of patients with mastocytosis, including less severe (cutane-
ous mastocytosis, indolent systemic mastocytosis; ISM) and 
more aggressive forms (smoldering systemic mastocytosis, 
systemic mastocytosis with associated haematological 
monoclonal disease (SM-AHNMD) [15]. In contrast to our 
results, they found a positive correlation between BST val-
ues and Z-score values, which was significant for the femo-
ral neck Z-score values. The lowest values were measured in 
the group of 14 patients with indolent systemic mastocytosis 
(ISM). This group had a mean BST value of 107.2 ng/ml. 
Patients with more severe forms of mastocytosis and higher 
mean BST values (256.7 for SSM, and 238.7 ng/ml for SM-
AHNMD, respectively) were found to have higher BMD in 
 
Fig. (1a). Correlation of basal serum tryptase levels (BST, in 
ng/ml) and bone mineral density Z-score values (Z-Score) of the 
lumbar spine region.  
Table 4. Study Participants According to Basal Serum Tryptase Categories  
Categories All BST 20-30 BST 30.9-50 BST 50.4-100 BST >100 
 (n=24) (n=10) (n=6) (n=5) (n=3) 
      
Age (years)      
mean (median) 48 (44) 48 (43) 49 (48) 43 (41) 49 (43) 
BMI (kg/m2)      
mean 26 26 28 24 27 
Z-score values   (means)      
Lumbar spine -0.6 0.2 -1.2 -1.5 -0.6 
Hip 0.3 0.6 0.3 -0.3 -0.3 
Femoral neck 0.0 0.5 0 -0.8 -0.6 
      
BST values in ng/ml; BMI = body mass index 
 
Fig. (1b). Correlation of basal serum tryptase levels (BST, in 
ng/ml) and bone mineral density Z-score values (Z-Score) of the 
hip region.  
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the lumbar spine, upper femur and distal third of the forearm, 
than patients with less severe forms of mastocytosis. The 
characteristics of our patients correspond most closely to the 
group of ISM patients described by Kushnir and colleagues 
in 2006. Therefore, their findings of lower Z-score values in 
the ISM group as compared to other forms of mastocytosis, 
and of a negative association of BMD with hypotensive epi-
sodes (corresponding to anaphylaxis [1]), do confirm our 
observations.  
Urine histamine metabolites have been used as surrogate 
marker of total mast cell burden, similar to BST levels [16, 
17]. Brumsen et al. showed in a study of 48 men with osteo-
porosis (mean age 47 years) that the level of urine methylhis-
tamine is negatively associated with BMD values, but posi-
tively with mast cell numbers in the bone marrow. Levels of 
urine methylhistamine were only mildly elevated (highest 
value 2.5 times the upper limit of the reference range). Four 
patients with increased N-methylhistamine levels in the urine 
were diagnosed to have systemic mastocytosis on the basis 
Fig. (3a). Receiver operating characteristic curve showing that the 
use of a cut-off value of BST level 20ng/ml leads to an area under 
the curve of 0.78 ± 0.11 for the identification of a low BMD at the 
hip (total hip region, p=0.03; CI: 0.56 – 0.99).  
 
Fig. (3b). Receiver operating characteristic curve showing that the 
use of a cut-off value of BST level 20ng/ml leads to an area under 
the curve of 0.74 ± 0.13 for the identification of a low BMD at the 
lumbar spine (p= 0.02; CI: 0.49 – 0.98).  
 
Fig. (2). Correlation of basal serum tryptase (BST) categories as shown in Table 4 and Z-score values (Z-Score) of the lumbar spine, total hip 
and femoral neck region. 
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of characteristic bone marrow mast cell infiltrates [18]. 
Studying 16 patients with varying degrees of mastocytosis as 
determined by the urine excretion of methylimidazoleacetic 
acid (highest value 8.6 times the upper limit of the reference 
range), Johansson et al. found lower BMD values and osteo-
porosis with vertebral fractures in patients with a moderately 
elevated mast cell mass (values between 1.4 and 4 times the 
upper limit of the reference range) [19]. In contrast, BMD 
was higher in patients with more strongly elevated mast cell 
mass (methylimidazoleacetic acid values 7.5 and 8.6 times 
the upper limit of the reference range). The overall associa-
tion between methylimidazoleacetic acid excretion and BMD 
in the hip was positive, similar to the study of Kushnir et al., 
who found a positive association between BST and femoral 
neck BMD Z-score values.  
In view of the studies discussed above the results of our 
study would suggest a U-shaped relationship between the 
total mast cell burden and BMD in the lumbar spine and hip 
regions [15, 18, 19]. We found the lowest BMD levels in 
patients with mildly and moderately elevated mast cell mass, 
corresponding to BST levels between approximately 30 and 
100 ng/ml. In a recent paper, a patient with secondary osteo-
porosis due to mastocytosis was described who had a BST 
value of 50.9 ng/ml [20]. The patient excluded from our 
study because of previous treatment with anti-osteoporotic 
medication also suffered from secondary osteoporosis due to 
biopsy proven systemic mastocytosis. His BST was 40.6 
ng/ml, again compatible with our finding of lowest BMD 
values and highest risk of osteoporosis between BST values 
of 30 and 100 ng/ml. In our patients no non-traumatic frac-
tures occurred during follow-up, but several patients were 
treated with bisphosphonates. 
This study has important limitations relating to the retro-
spective design, the high exclusion rate of potentially eligi-
ble patients, and the selection of patients (e.g. high propor-
tion of females among study participants). Furthermore, 
there is no control group with anaphylaxis and normal BST 
values and we cannot provide any follow-up information of 
those patients from our unit with similar BST values and 
clinical signs but who did not undergo DXA measurement. 
Many parameters relevant to BMD and to exclusion of sec-
ondary causes of osteoporosis (parathormone, vitamin D, 
calcium, phosphorus, thyroid hormone, sex hormones, renal 
excretion) were not evaluated due to the retrospective nature 
of this study. However, our observations are in line with pre-
vious reports and underline that an increase of BST in pa-
tients with signs of mastocytosis may correlate with a loss of 
BMD. In patients with BST values between 30 and 100 
ng/ml the prediction of a low BMD would eventually be pos-
sible with a sensitivity of 92% and a specificity of 70% when 
using a cut-off value of BST of 27 ng/ml. However, our this 
interpretation is limited because of the important variability 
of the association between BMD and BST observed in our 
study. However, this observation is based on a very limited 
number of patients and, therefore, large-scale prospective 
studies including patients with normal BST values are neces-
sary to confirm our findings and to further investigate the 
hypothesis of a U-shaped association between BMD and 
BST.  
In conclusion we confirm previous studies indicating an 
increased risk of low BMD values in patients with moder-
ately elevated BST levels and anaphylaxis. Therefore BMD 
measurement using DXA should be considered in such pa-
tients. In this small series of selected patients we suggest a 
tendency of higher BMD values in those patients with the 
highest BST values, a finding that was described by previous 
authors, too. 
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